Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 73.54% | -83.47% | |||
| Gross Profit | -73.54% | 83.47% | |||
| SG&A Expenses | -1.95% | -20.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.15% | -6.94% | |||
| Operating Income | 1.15% | 6.94% | |||
| Income Before Tax | 69.36% | -55.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.36% | -55.26% | |||
| Earnings from Discontinued Operations | -100.00% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -117.61% | 370.08% | |||
| EBIT | 1.15% | 6.94% | |||
| EBITDA | 0.06% | 7.21% | |||
| EPS Basic | -115.70% | 368.14% | |||
| Normalized Basic EPS | 103.64% | -54.13% | |||
| EPS Diluted | -116.27% | 364.36% | |||
| Normalized Diluted EPS | 103.64% | -54.13% | |||
| Average Basic Shares Outstanding | 12.23% | 0.75% | |||
| Average Diluted Shares Outstanding | 12.23% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||